Literature DB >> 9241733

Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins.

H Mikkola1, L Muszbek, G Haramura, E Hämäläinen, A Jalanko, A Palotie.   

Abstract

Factor XIII deficiency is an autosomal recessive bleeding disorder that is largely caused by various mutations in FXIII A-subunit gene. Characteristically, the patients lack both A-subunit activity and antigen in the circulation. Here we have analysed the consequences of four missense mutations (Met242-->Thr, Arg252-->Ile, Arg326-->Gln, Leu498 to Pro) and one stop mutation (Arg661-->Stop) in the FXIII A-subunit gene by expression in COS-cells. After transient transfection each mutant cDNA expressed mRNA at an equal level to the wild type FXIII. However, the mutant polypeptides accumulated in the cells in significantly reduced quantities and demonstrated only very low enzymatic activity. Analysis of immunoprecipitated metabolically labelled polypeptides demonstrated remarkable instability and intracellular degradation of all mutant FXIII proteins. These results verify the deleterious nature of the individual amino acid changes and confirm that protein instability and susceptibility to proteolysis are consequences of the mutations, as predicted from the three-dimensional model of crystallised FXIII A-subunit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241733

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

Authors:  Shoko Maeda; Wei Guang Zhang; Masayoshi Souri; Vivien C Yee; Akitada Ichinose
Journal:  J Biochem       Date:  2012-08-25       Impact factor: 3.387

2.  Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency.

Authors:  Lara Rizzotto; Mirko Pinotti; Paolo Pinton; Rosario Rizzuto; Francesco Bernardi
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

Review 3.  How to Assess Founder Effect in Patients with Congenital Factor XIII Deficiency.

Authors:  Hojat Shahraki; Akbar Dorgalaleh; Majid Fathi; Shadi Tabibian; Shahram Teimourian; Hasan Mollanoori; Alireza Khiabani; Farhad Zaker
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.